Image (Tascenso 01)
Tascenso Odt Tablet, Orally Disintegrating
Product Images NDC 70709-062
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tascenso Odt (NDC 70709-062). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cycle Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Tascenso 02)
Figure 1 (Tascenso 03)
Principal Display Panel (Tascenso 04)
Principal Display Panel (0.25 mg Tablet Blister Pack Carton)
TASCENSO ODT is a medication containing Fingolimod lauryl sulfate that comes in the form of orally disintegrating tablets. Each tablet contains 0.47 mg of the active ingredient. The tablets should be stored in a dry and cool place, away from direct sunlight, and should not be pushed through the foil packaging. It is recommended to take one tablet by placing it on the tongue and allowing it to dissolve. The prescribed dosage should be followed as indicated on the prescription. TASCENSO ODT is manufactured by Cycle Pharmaceuticals in the United Kingdom. The medication comes in blister packs of 10 tablets and each carton has 3 bister cards. The pharmacist should provide an accompanying medication guide to the patient.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
